Gil, M.; Winiarczyk, K.; Krawczyk, P.; Wojas-Krawczyk, K.; Łomża-Łaba, A.; Obara, A.; Gajek, Ł.; Reszka, K.; Tysarowski, A.; Buczkowski, J.;
et al. Effectiveness of First-Line Treatment with Anaplastic Lymphoma Kinase and ROS1 Protoncogene Inhibitors in Non-Small Cell Lung Cancer Patients—Real-World Evidence of Two Polish Cancer Centers. Cancers 2025, 17, 1253.
https://doi.org/10.3390/cancers17071253
AMA Style
Gil M, Winiarczyk K, Krawczyk P, Wojas-Krawczyk K, Łomża-Łaba A, Obara A, Gajek Ł, Reszka K, Tysarowski A, Buczkowski J,
et al. Effectiveness of First-Line Treatment with Anaplastic Lymphoma Kinase and ROS1 Protoncogene Inhibitors in Non-Small Cell Lung Cancer Patients—Real-World Evidence of Two Polish Cancer Centers. Cancers. 2025; 17(7):1253.
https://doi.org/10.3390/cancers17071253
Chicago/Turabian Style
Gil, Michał, Kinga Winiarczyk, Paweł Krawczyk, Kamila Wojas-Krawczyk, Aleksandra Łomża-Łaba, Adrian Obara, Łukasz Gajek, Katarzyna Reszka, Andrzej Tysarowski, Jarosław Buczkowski,
and et al. 2025. "Effectiveness of First-Line Treatment with Anaplastic Lymphoma Kinase and ROS1 Protoncogene Inhibitors in Non-Small Cell Lung Cancer Patients—Real-World Evidence of Two Polish Cancer Centers" Cancers 17, no. 7: 1253.
https://doi.org/10.3390/cancers17071253
APA Style
Gil, M., Winiarczyk, K., Krawczyk, P., Wojas-Krawczyk, K., Łomża-Łaba, A., Obara, A., Gajek, Ł., Reszka, K., Tysarowski, A., Buczkowski, J., Chmielewska, I., Jankowski, T., Szuba-Gil, M., Strzemski, M., Kowalski, D. M., Milanowski, J., & Krzakowski, M.
(2025). Effectiveness of First-Line Treatment with Anaplastic Lymphoma Kinase and ROS1 Protoncogene Inhibitors in Non-Small Cell Lung Cancer Patients—Real-World Evidence of Two Polish Cancer Centers. Cancers, 17(7), 1253.
https://doi.org/10.3390/cancers17071253
